biostudies-literatureZarranz-Ventura JRoche (F. Hoffmann-La Roche Ltd)Roche3306-3313https://www.ebi.ac.uk/biostudies/studies/S-EPMC12669756biostudies-literatureUnknown39(18)<h4>Background</h4>To evaluate treatment intervals at 12/24 months following initiation of anti-VEGF therapy and to characterise the clinical profile of neovascular AMD (nAMD) patients achieving extended treatment intervals (≥12 and ≥16 weeks).<h4>Methods</h4>National, retrospective, real-world study using data from the validated web-based Fight Retinal Blindness (FRB!) registry. Treatment-naive nAMD eyes managed with approved first-generation intravitreal VEGF inhibitors (ranibizumab, aflibercept 2 mg) and followed for at least 12 months were included. A subanalysis was conducted on eyes receiving a number of injections within range of a treat and extend (TAE) regimen at 12 and 24 months.<h4>Results</h4>A total number of 1278/557 treatment-naïve nAMD eyes within the TAE range category comEye (London, England)Treatment intervals with first-generation anti-vascular endothelial growth factor drugs: evaluating the unmet need in a real-world neovascular age-related macular degeneration national database.PMC12669756Independent research collaborationCarreno ECastillon Torre LJParrado-Carrillo APerez Rivases GCatalan Munoz PLorenzo Parra DChinchurreta Capote ACarnota-Mendez PDel-Barrio-Lopez-de-Ipina ZSanchez JGonzalez Guijarro JAbraldes Lopez-Veiga MJGomez AAlonso ECarrillo SGarcia Zamora MArnaiz PGismero-Moreno SCasaroli-Marano RPVega-Gonzalez RGallego-Pinazo RCobos EDiaz-de-Durana-Santa-Coloma EMontejano-Milner RHernandez-Martinez AFernandez-Robredo PPareja Esteban JZarranz-Ventura JMunoz Sanz NBelmonte Grau MCilveti ERuiz Moreno JMGalletero LGarcia-Lunar PRodriguez-Cid MJSerrano AMiguel-Escuder LAlarcon-Valero ICobo-Soriano RTorres-Borrego CAcebes Garcia MLavid de Los Mozos FJGarrido MSanchez-Vela LFigueroa MSGomez-Moreno ATena Sempere MEBrosa HFernandez Varela PBroc-Iturralde LDolz-Marco REspineira Perinan MAHonrubia Grijalbo ALondono GRodriguez Hurtado FArias-Barquet LMartin-Pinardel RMantrana Bermejo MEValldeperas XAscaso-Puyuelo FJFlores-Moreno IRodriguez-Fernandez CACastro Casal NBoned Murillo Ade Fatima Alvarez Gil MSalinas Martinez EGaray-Aramburu GGrau JOlivera MHerrero-Diaz IQuintero Gonzalez CPinas Garcia PMoreno Gutierrez JABernal-Morales CRodriguez-Feijoo DVilaplana Mira FMendez-Vazquez CVentura NRethati CSaenz de Viteri MFernandez-Hortelano AGarcia-Martinez JRSararols-Ramsay LAparicio Sanchis SCampos Figueroa PMarias-Perez SRubio Cid SIzquierdo-Serra JBanon KBakkali El Bakkali IAzrak Haskour CZapata MAArrazola Berrizbeitia MTDiago TPina-Marin BBatlle-Ferrando SCalvo PRuiz-Moreno OCacelliere Fernandez JCiancas EFonollosa Calduch ALarrauri-Arana AAlforja SFigueras-Roca MVelazquez-Villoria DGarcia-Arumi JMoll-Udina ASanchez JABarnes CFernandez-Bonet MRodriguez-Maqueda MGarcia-Layana AAsencio Duran MZarallo-Gallardo JLozano-Escobar IMoreno-Martin PEscobar-Barranco JJCholbi MFRB SPAIN study groupArruabarrena CGomez Sanchez SDiaz Barreda MDRuiz-Del-Tiempo MPPinero Sanchez AGomez Conde MLRodriguez-Nunez MPuzo MGonzalez Escobar ABFernandez Rodriguez MISotomayor Toribio MCampo Gesto AGonzalez-Lopez JJOliver NAldazabal-Echeveste MRecalde SLiano-Sanz Diez de Ulzurrun GfalseTreatment intervals with first-generation anti-vascular endothelial growth factor drugs: evaluating the unmet need in a real-world neovascular age-related macular degeneration national database.<h4>Background</h4>To evaluate treatment intervals at 12/24 months following initiation of anti-VEGF therapy and to characterise the clinical profile of neovascular AMD (nAMD) patients achieving extended treatment intervals (≥12 and ≥16 weeks).<h4>Methods</h4>National, retrospective, real-world study using data from the validated web-based Fight Retinal Blindness (FRB!) registry. Treatment-naive nAMD eyes managed with approved first-generation intravitreal VEGF inhibitors (ranibizumab, aflibercept 2 mg) and followed for at least 12 months were included. A subanalysis was conducted on eyes receiving a number of injections within range of a treat and extend (TAE) regimen at 12 and 24 months.<h4>Results</h4>A total number of 1278/557 treatment-naïve nAMD eyes within the TAE range category com2025-01-01T00:00:00Z2025 Dec2026-06-05T20:37:59.08Z2026-05-21T03:12:52.153ZS-EPMC126697564110255410.1038/s41433-025-03996-8